Aldeyra Therapeutics Inc (STU:137)
€ 5.158 0.084 (1.66%) Market Cap: 303.87 Mil Enterprise Value: 206.88 Mil PE Ratio: 0 PB Ratio: 3.34 GF Score: 40/100

Q3 2020 Aldeyra Therapeutics Inc Earnings Call Transcript

Nov 05, 2020 / 01:00PM GMT
Release Date Price: €5.9 (+2.61%)
Operator

Good morning, and welcome to the Aldeyra Therapeutics Third Quarter 2020 Financial Results Conference Call. (Operator Instructions)

At this time, I would like to turn the call over to Mr. Joshua Reed, the company's Chief Financial Officer. Please go ahead, sir.

Joshua Reed
Aldeyra Therapeutics, Inc. - CFO

Thank you, and good morning, everyone. On the call with me are Dr. Todd Brady, Aldeyra's President and Chief Executive Officer; and David McMullin, our Chief Business Officer. Dr. Brady will begin with an overview of our recent highlights and expected upcoming clinical milestones. I will discuss our third quarter financial results, and then we'll take your questions.

Please note that this morning's conference call contains forward-looking statements regarding future events and the future performance of Aldeyra. Forward-looking statements include statements regarding the timing of planned clinical trial initiations, Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot